Bamlanivimab vs placebo
Development of clinical COVID‐19 symptoms within 30 days · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
The review found no eligible studies for this question.
1 finding from 1 review
- SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 2022 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found